Is PT-141 (Bremelanotide) Legal in Europe?
Is PT-141 (bremelanotide) legal in Europe? It is FDA-approved as Vyleesi in the US, but holds no EMA authorisation and never even completed an EU application, so in Europe it is a research reagent only. An honest, source-cited look at what 'legal' really means here.
PT-141 (bremelanotide) is approved in the United States as the prescription medicine Vyleesi, but it has never been authorised by the European Medicines Agency (EMA) or any EU member state, and no EU application was ever even completed. So no EU physician can lawfully prescribe it. In Europe it is supplied legitimately only as a research-use-only reference material, never for human use. The honest question is not 'is PT-141 legal' but 'legal for what': handling it as a characterised research reagent is lawful in much of the EU; using or supplying it for human consumption is not.
PT-141 — bremelanotide — sits in one of the most misread regulatory positions of any peptide: in the United States it is a prescription medicine you can collect at a pharmacy, and across the whole of Europe it has no medicinal standing at all, having never even completed an application to the European regulator. That gap is exactly where the question “is PT-141 legal in Europe” goes wrong — because legality was never a property of the molecule. It is a property of what you intend to do with it, and in which jurisdiction.
Is PT-141 approved as a medicine in Europe?
No. Bremelanotide has not been authorised as a medicine by the European Medicines Agency (EMA), and it carries no marketing authorisation in any individual EU member state.1 Because it holds no authorisation anywhere in the Union, there is no lawful route by which an EU physician can prescribe it as a medicine. This is the decisive fact, and it does most of the work in any honest answer: PT-141 is not a licensed European drug that happens to be hard to find — it is a compound that has never cleared the EU regulatory gate, and, unlike many peptides, it never even reached it.
That is true even though bremelanotide has a real research history. The compound is a cyclic heptapeptide and a melanocortin-receptor agonist, originally explored as a sunless-tanning candidate and later studied as a melanocortin agonist in the context of sexual dysfunction in laboratory and clinical research.4 A documented research record is not the same as a European approval; one is evidence generated in a lab or clinic, the other is a legal status conferred by a regulator after formal review. Bibliographic study describes what a molecule does in a research setting; it says nothing about whether a person may lawfully be given it.
So how can PT-141 be “approved” at all — and is Vyleesi the European version?
This is the heart of the confusion, and it deserves a blunt correction. PT-141 is approved in the United States, where the FDA authorised it in June 2019 under the brand name Vyleesi as a prescription-only treatment for acquired, generalised hypoactive sexual desire disorder in premenopausal women.2 That US status is genuine. But it is widely — and wrongly — implied that “Vyleesi is approved in Europe.” It is not. Vyleesi is a United States approval only; there is no EMA marketing authorisation, no member-state authorisation, and there was never even a completed EU application. EU development rights were licensed to Gedeon Richter in 2014, but that agreement was terminated in 2015, before any submission to the EMA, and the rights reverted to the originator.3 The honest summary is therefore even starker than for most unapproved peptides: bremelanotide did not fail an EU review — it never had one.
| Question | Status under the verified facts |
|---|---|
| Approved as a medicine in the EU (EMA or member state) | No — never authorised |
| EU regulatory application ever completed | No — Richter licence (2014) terminated in 2015 before any EMA submission |
| Approved as a medicine outside the EU | Yes — FDA-approved as Vyleesi (US, 2019), prescription-only |
| US approval valid inside the EU | No — does not transfer to the Union |
| Prescribable by an EU physician | No — no lawful route exists |
| Sold as a research chemical (RUO reference material) | Yes — in much of the EU |
| Supply or use for human consumption in the EU | Not permitted |
| Controlled narcotic / psychotropic / novel food | No to all three |
| Named on the WADA Prohibited List | Not explicitly — but see the S0 caveat |
PT-141 at a glance: a US approval and a research-reagent status in Europe are both true, and neither makes it a European medicine.
Why is PT-141 sold across Europe, then?
Because there are two distinct markets, and only one of them is legitimate. PT-141 is supplied in much of the EU strictly as a research chemical — a characterised reference material offered on a “for research use only” basis.1 Handling it that way is lawful in many member states. What is not permitted is selling, labelling or supplying bremelanotide for human use. Under Directive 2001/83/EC, a product can become a “medicinal product” either by presentation — how it is described and marketed — or by function;5 so the moment a product is offered or described for human consumption, the research-use-only label is voided and it enters the regulated medicines regime it has never qualified for in the EU. The label is not a magic word; it describes a use, and it survives only as long as that use does.
PT-141 is legal to handle as a research reference material in much of the EU, and there is no lawful route to use it as a medicine anywhere in the Union. Both statements are true at the same time.
Zero EU regulatory applications for bremelanotide were ever completed — the 2014 European licence was terminated in 2015 before any EMA submission.
Does the law say the same thing in every EU country?
No, and this is where confident blanket claims fail. Each member state applies its own national medicines law, transposed from the shared EU framework of Directive 2001/83/EC.5 A directive is not a single rulebook applied identically across the bloc; it is a common architecture that each country writes into its own national law, so the classification, handling and enforcement around an unapproved compound can differ from one member state to the next even though the underlying European framework is the same. Bremelanotide is not a scheduled narcotic or psychotropic in this picture, it is not a novel food, and in Spain it is not on the anabolic or doping-control list — but none of that is a clean bill of legal health. Possession, importation or use for human purposes can attract penalties in some jurisdictions even where the same compound circulates freely as a research reagent elsewhere.
Is PT-141 banned in sport?
Here the honest answer is an ambiguity, not a verdict. Bremelanotide is not explicitly named on the World Anti-Doping Agency’s Prohibited List, and melanocortin-receptor agonists are not listed as a named class.6 That is not the same as being permitted. WADA’s catch-all S0 clause covers non-approved substances — pharmacological agents with no current regulatory approval by any governmental health authority for human therapeutic use.6 Bremelanotide complicates that reading, because it does hold a US approval, so it is not straightforwardly a wholly “non-approved” substance in the way a never-registered peptide would be. The realistic conclusion is not a tidy “banned” or “allowed” but a genuine grey zone: an athlete should treat its status as unresolved rather than safe, and seek a current, case-specific ruling rather than relying on the absence of its name.6
What should an honest answer concede?
Plenty. The US approval is real, and it genuinely does not help you in the EU. The absence of any completed EU application is not a technicality — it means there is no European file, no European label, and no European route, only a foreign one that does not cross the border. The country-by-country variation is real, not a rhetorical hedge: an arrangement that is unremarkable in one member state may attract penalties in another once human use enters the frame.5 The doping position is unsettled rather than decided. And because PT-141 is associated in popular writing with a sexual-function indication, one caveat bears repeating above all the others: nothing in this article describes, frames or hints at any human use of the compound. The legality that exists is the legality of a research reagent, and it evaporates the instant the use case changes. For the wider framework Condor Research applies to every compound in this category, see the regulatory position.
Everything Condor Research supplies in this category is a characterised research reference material, sold strictly for research use only.1 It is not an approved or prescribable EU medicine, it is not intended for human or veterinary use, and nothing here is a recommendation to use any compound. This article is for informational purposes only and is not legal advice; responsibility for knowing and complying with applicable local regulation rests with the purchaser. The distinction between a regulated, approved medicine and an RUO reference material is not a formality — it is the entire legal and scientific basis on which legitimate supply rests.
Research Use Only. This material is supplied strictly as a characterised reference reagent for in-vitro and laboratory research. It is not an approved medicine, is not for human or veterinary use, and nothing above is medical or legal advice. — Condor Research · Scientific desk
- PT-141 (bremelanotide) is FDA-approved in the US as Vyleesi, but it holds no EMA marketing authorisation and is not approved in any EU member state, so no EU physician can lawfully prescribe it.
- There has never even been a completed EU regulatory application: EU development rights were licensed to Gedeon Richter in 2014, but that deal was terminated before any EMA submission, so the compound never cleared — or even entered — the EU approval gate.
- A US approval does not transfer to the EU. The American Vyleesi authorisation has no legal standing under the EU medicines framework (Directive 2001/83/EC), which each member state transposes into its own national law.
- In the EU, PT-141 is supplied legitimately only as a research chemical (research use only); offering, labelling or supplying it for human use is not permitted, and a "research use only" label is voided the moment a product is presented for human consumption.
- PT-141 is not a controlled narcotic, not a novel food, and not on Spain's doping-control list; it is not explicitly named on the WADA Prohibited List either, but its doping status is an honest ambiguity rather than a clean clearance.
Is PT-141 (bremelanotide) approved as a medicine anywhere in the EU?
No. Bremelanotide holds no marketing authorisation from the European Medicines Agency and is not approved in any individual EU member state, so no EU physician can lawfully prescribe it. It is supplied legitimately in Europe only as a research-use-only reference material, not as an approved drug.
But isn't Vyleesi approved? Doesn't that count in Europe?
Vyleesi is a United States FDA approval only. It is not approved by the EMA, and there has never even been a completed EU application — the 2014 European development licence was terminated in 2015 before any EMA submission. A marketing authorisation granted outside the EU has no legal standing inside it under Directive 2001/83/EC, so a US approval creates no lawful route to prescribe or supply bremelanotide as a medicine in the Union.
If it is sold in Europe, doesn't that mean it is legal to use?
Not for human use. PT-141 is supplied in much of the EU strictly as a research chemical. Selling, labelling or supplying it for human consumption is not permitted; the legality attaches to handling it as a reference material, not to using it on a person.
Is PT-141 a controlled or scheduled narcotic in the EU?
No, bremelanotide is not a scheduled narcotic or psychotropic, it is not a novel food, and it is not on Spain's anabolic or doping-control list. However, because each member state applies its own national medicines law under the EU framework, possession, importation or use for human purposes can still carry penalties in some jurisdictions, so the status varies country to country.
Is PT-141 banned in sport under WADA rules?
It is not explicitly named on the WADA Prohibited List, and melanocortin agonists are not a named class, so this is an honest ambiguity rather than a clean answer either way. The catch-all S0 clause covers substances with no current regulatory approval for human therapeutic use; bremelanotide does hold a US approval, which complicates that reading, but athletes should still treat its status as unresolved rather than safe.